VEGFA and neoplasm: Several VEGFR humanised anti-VEGF monoclonal antibody (bevacizumab) and small-molecule VEGFR-2 kinase inhibitors (Sorafenib4,5 Sunitinib6,7, and Pazopanib8) have been approved, and these have demonstrated clinical benefits in the treatment of some tumours with manageable side effects.